Header Logo

Connection

DONALD PARSONS to Neoplasms

Back to Details
This is a "connection" page, showing publications DONALD PARSONS has written about Neoplasms.
DONALD PARSONS
Connection Strength
2.471
Neoplasms
  1. Recent Advancements and Innovations in Pediatric Precision Oncology. J Pediatr Hematol Oncol. 2024 07 01; 46(5):262-271.
    View in: PubMed
    Score: 0.332
  2. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
    View in: PubMed
    Score: 0.332
  3. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2224-2234.
    View in: PubMed
    Score: 0.285
  4. Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. J Clin Oncol. 2014 Jul 20; 32(21):2203-5.
    View in: PubMed
    Score: 0.166
  5. Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study. JCO Precis Oncol. 2024 Sep; 8:e2400187.
    View in: PubMed
    Score: 0.084
  6. Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258.
    View in: PubMed
    Score: 0.084
  7. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. Oncologist. 2024 Aug 05; 29(8):723-e1093.
    View in: PubMed
    Score: 0.084
  8. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. Oncologist. 2024 Jul 05; 29(7):638-e952.
    View in: PubMed
    Score: 0.083
  9. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3? inhibitors in children and adolescents with cancer. Eur J Cancer. 2024 Aug; 207:114145.
    View in: PubMed
    Score: 0.083
  10. Genomic sequencing research in pediatric cancer care: Decision making, attitudes, and perceived utility among adolescents and young adults and their parents. Genet Med. 2024 Aug; 26(8):101168.
    View in: PubMed
    Score: 0.083
  11. Families' experiences accessing care after genomic sequencing in the pediatric cancer context: "It's just been a big juggle". J Genet Couns. 2024 Dec; 33(6):1337-1350.
    View in: PubMed
    Score: 0.081
  12. Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30563.
    View in: PubMed
    Score: 0.078
  13. Views of Adolescents and Young Adults with Cancer and Their Oncologists Toward Patients' Participation in Genomic Research. J Adolesc Young Adult Oncol. 2023 10; 12(5):773-781.
    View in: PubMed
    Score: 0.075
  14. A Validation Framework for Somatic Copy Number Detection in Targeted Sequencing Panels. J Mol Diagn. 2022 07; 24(7):760-774.
    View in: PubMed
    Score: 0.072
  15. Inferring clonal composition from multiple tumor biopsies. NPJ Syst Biol Appl. 2020 08 25; 6(1):27.
    View in: PubMed
    Score: 0.064
  16. Precision Medicine in Pediatric Oncology. Surg Oncol Clin N Am. 2020 01; 29(1):63-72.
    View in: PubMed
    Score: 0.060
  17. Exome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents. Patient Educ Couns. 2019 04; 102(4):680-686.
    View in: PubMed
    Score: 0.056
  18. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017 05 01; 109(5).
    View in: PubMed
    Score: 0.051
  19. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200.
    View in: PubMed
    Score: 0.050
  20. Somatic cancer variant curation and harmonization through consensus minimum variant level data. Genome Med. 2016 11 04; 8(1):117.
    View in: PubMed
    Score: 0.049
  21. Precision medicine in pediatric oncology: Lessons learned and next steps. Pediatr Blood Cancer. 2017 03; 64(3).
    View in: PubMed
    Score: 0.049
  22. Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories. J Natl Cancer Inst. 2016 Apr; 108(4).
    View in: PubMed
    Score: 0.046
  23. Is Whole-Exome Sequencing an Ethically Disruptive Technology? Perspectives of Pediatric Oncologists and Parents of Pediatric Patients With Solid Tumors. Pediatr Blood Cancer. 2016 Mar; 63(3):511-5.
    View in: PubMed
    Score: 0.046
  24. Pediatric Cancer Genetics Research and an Evolving Preventive Ethics Approach for Return of Results after Death of the Subject. J Law Med Ethics. 2015; 43(3):529-37.
    View in: PubMed
    Score: 0.043
  25. Responsibility, culpability, and parental views on genomic testing for seriously ill children. Genet Med. 2019 12; 21(12):2791-2797.
    View in: PubMed
    Score: 0.015
  26. Portero versus portador: Spanish interpretation of genomic terminology during whole exome sequencing results disclosure. Per Med. 2017 11; 14(6):503-514.
    View in: PubMed
    Score: 0.013
  27. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19; 360(8):765-73.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.